Citius Pharmaceuticals, Inc.(CTXR)Earnings, Financials & Key Ratios
CTXR•NASDAQ
$0.67
$12M mkt cap·Price updated May 6, 2026
AboutCitius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.Show more
- Revenue$0
- EBITDA-$38M+8.3%
- Net Income-$37M+4.4%
- EPS (Diluted)-3.38+43.4%
- ROE-49.38%-4.4%
- ROIC-39.53%+14.3%
- Debt/Equity0.02+559.4%
- Interest Coverage-143.87
CTXR Key Insights
Citius Pharmaceuticals, Inc. (CTXR) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Share count reduced 4.5% through buybacks
- ✓Trading at only 0.1x book value
✗Weaknesses
- ✗Weak momentum: RS Rating 14 (bottom 14%)
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
CTXR Price & Volume
Citius Pharmaceuticals, Inc. (CTXR) stock price & volume — 10-year historical chart
Loading chart...
CTXR Growth Metrics
Citius Pharmaceuticals, Inc. (CTXR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM4.36%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM37.13%
Return on Capital
10 Years-49.62%
5 Years-36.38%
3 Years-42.87%
Last Year-46.18%
CTXR Peer Comparison
Citius Pharmaceuticals, Inc. (CTXR) competitors in Commercial Specialty Pharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NKTR | 1.67B | 85.09 | -8.75 | -43.89% | -192.87% | -356.81% | 0.95 | |
 HALO | 7.81B | 66.35 | 25.92 | 37.55% | 22.69% | 6.49% | ||
 PRGO | 1.69B | 12.26 | -1.19 | -2.75% | -43.5% | -50.65% | 1.35 | |
 PAHC | 2.38B | 58.64 | 49.28 | 27.37% | 6.29% | 30.81% | 2.67 | |
 ETON | 815.47M | 30.15 | -177.35 | 104.94% | -5.75% | -18.84% | 0.35 | |
 TLRY | 671.17M | 5.76 | -0.17 | 4.84% | -252.55% | -136.55% | 0.22 | |
 MNKD | 1.1B | 3.56 | 178 | 22.23% | -6.63% | |||
 ACRS | 575.99M | 4.78 | -9.02 | -58.19% | -8.3% | -62.98% |
Compare CTXR vs Peers
Citius Pharmaceuticals, Inc. (CTXR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CTXR Income Statement
Citius Pharmaceuticals, Inc. (CTXR) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Sep'17 | Sep'18 | Sep'19 | Sep'20 | Sep'21 | Sep'22 | Sep'23 | Sep'24 | Sep'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 2.63K | 1.75K | 893 | 152.36K | 164.87K | 179.68K | 194.32K | 209.61K | 214.25K |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | -2.63K▲ 0% | -1.75K▲ 33.4% | -893▲ 49.1% | -152.36K▼ 16962.0% | -164.87K▼ 8.2% | -179.68K▼ 9.0% | -194.32K▼ 8.1% | -209.61K▼ 7.9% | -214.25K▼ 2.2% |
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | -95.98% | 33.4% | 49.06% | -16962.04% | -8.21% | -8.98% | -8.15% | -7.87% | -2.21% |
| Operating Expenses | 9.99M | 13.79M | 15.6M | 17.71M | 23.53M | 33.32M | 36.73M | 42M | 38.31M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 7.05M | 7.23M | 7M | 8.9M | 11.29M | 15.66M | 21.91M | 18.25M | 18.53M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - |
| Research & Development | 2.94M | 6.56M | 8.6M | 8.81M | 12.24M | 17.66M | 14.82M | 11.91M | 9.16M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11.84M | 10.62M |
| Operating Income | -9.99M▲ 0% | -13.79M▼ 38.1% | -15.6M▼ 13.1% | -17.71M▼ 13.5% | -23.53M▼ 32.9% | -33.32M▼ 41.6% | -36.73M▼ 10.3% | -42M▼ 14.3% | -38.53M▲ 8.3% |
| Operating Margin % | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | -34.06% | -38.08% | -13.12% | -13.54% | -32.87% | -41.58% | -10.25% | -14.33% | 8.26% |
| EBITDA | -9.98M | -13.79M | -15.6M | -17.56M | -23.37M | -33.14M | -36.54M | -41.79M | -38.31M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -34.05% | -38.1% | -13.13% | -12.57% | -33.08% | -41.81% | -10.26% | -14.36% | 8.32% |
| D&A (Non-Cash Add-back) | 2.63K | 1.75K | 893 | 152.36K | 164.87K | 179.68K | 194.32K | 209.61K | 214.25K |
| EBIT | -9.99M | -12.52M | -15.55M | -17.53M | -23.04M | -33.06M | -31.97M | -38.85M | -38.42M |
| Net Interest Income | -849.98K | 0 | 36.22K | 52.39K | 250.99K | 0 | 1.18M | 758K | -157.7K |
| Interest Income | 806 | 0 | 52.66K | 68.07K | 261.82K | 251.4K | 1.18M | 758K | 110.08K |
| Interest Expense | 850.79K | 15.84K | 16.44K | 15.67K | 10.84K | 251.4K | 0 | 0 | 267.78K |
| Other Income/Expense | -398.64K | 1.25M | 36.22K | 162.6K | 477.46K | 251.4K | 4.77M | 3.15M | -157.7K |
| Pretax Income | -10.38M▲ 0% | -12.54M▼ 20.7% | -15.56M▼ 24.1% | -17.55M▼ 12.8% | -23.05M▼ 31.4% | -33.06M▼ 43.4% | -31.97M▲ 3.3% | -38.85M▼ 21.5% | -38.68M▲ 0.4% |
| Pretax Margin % | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 16.44K | 0 | 0 | 576K | 576K | 576K | 1.06M |
| Effective Tax Rate % | 0% | 0% | -0.11% | 0% | 0% | -1.74% | -1.8% | -1.48% | -2.73% |
| Net Income | -10.38M▲ 0% | -12.54M▼ 20.7% | -15.58M▼ 24.3% | -17.55M▼ 12.6% | -23.13M▼ 31.8% | -33.64M▼ 45.5% | -32.54M▲ 3.3% | -39.14M▼ 20.3% | -37.43M▲ 4.4% |
| Net Margin % | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | -25.18% | -20.72% | -24.26% | -12.64% | -31.78% | -45.47% | 3.26% | -20.27% | 4.36% |
| Net Income (Continuing) | -10.38M | -12.54M | -15.56M | -17.55M | -23.05M | -33.64M | -32.54M | -39.43M | -39.74M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 600.38K | 600.38K | 600.38K | 4.02M | 9.98M |
| EPS (Diluted) | -1.89▲ 0% | -1.17▲ 38.1% | -0.77▲ 34.2% | -0.45▲ 41.6% | -5.64▼ 1153.3% | -5.76▼ 2.1% | -5.57▲ 3.3% | -5.97▼ 7.2% | -3.38▲ 43.4% |
| EPS Growth % | 17.47% | 38.1% | 34.19% | 41.56% | -1153.33% | -2.13% | 3.3% | -7.18% | 43.38% |
| EPS (Basic) | -1.89 | -1.17 | -0.77 | -0.45 | -5.64 | -5.76 | -5.57 | -5.97 | -3.38 |
| Diluted Shares Outstanding | 365.5K | 715.46K | 1.34M | 2.61M | 7.24M | 9.74M | 10.09M | 11.59M | 11.07M |
| Basic Shares Outstanding | 365.5K | 715.46K | 1.34M | 2.61M | 7.24M | 9.74M | 9.74M | 11.59M | 11.07M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
CTXR Balance Sheet
Citius Pharmaceuticals, Inc. (CTXR) balance sheet — assets, liabilities & shareholders' equity
| Line item | Sep'17 | Sep'18 | Sep'19 | Sep'20 | Sep'21 | Sep'22 | Sep'23 | Sep'24 | Sep'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 3.42M | 10.06M | 7.94M | 13.98M | 72.81M | 44.56M | 34.37M | 14.22M | 27.93M |
| Cash & Short-Term Investments | 3.2M | 9.18M | 7.89M | 13.86M | 70.07M | 41.71M | 26.48M | 3.25M | 4.25M |
| Cash Only | 3.2M | 9.18M | 7.89M | 13.86M | 70.07M | 41.71M | 26.48M | 3.25M | 4.25M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 818.34K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.27M | 22.29M |
| Days Inventory Outstanding | - | - | - | - | - | - | - | 14.4K | 37.97K |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Non-Current Assets | 20.99M | 20.99M | 21.04M | 29.79M | 69.61M | 69.44M | 69.24M | 102.43M | 103M |
| Property, Plant & Equipment | 3.24K | 1.48K | 590 | 987.78K | 829.85K | 650.17K | 455.86K | 246.25K | 818.69K |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | - |
| Goodwill | 1.59M | 1.59M | 1.59M | 9.35M | 9.35M | 9.35M | 9.35M | 9.35M | 9.35M |
| Intangible Assets | 19.4M | 19.4M | 19.4M | 19.4M | 59.4M | 59.4M | 59.4M | 92.8M | 92.8M |
| Long-Term Investments | 0 | 0 | 0 | 16.92M | 29.18M | 0 | 44.91M | 0 | 0 |
| Other Non-Current Assets | 2.17K | 2.17K | 57.09K | 57.09K | 38.06K | 39.97M | -44.88M | 38.06K | 38.06K |
| Total Assets | 24.42M▲ 0% | 31.05M▲ 27.2% | 28.99M▼ 6.6% | 43.77M▲ 51.0% | 142.43M▲ 225.4% | 114M▼ 20.0% | 103.61M▼ 9.1% | 116.65M▲ 12.6% | 130.94M▲ 12.2% |
| Asset Turnover | - | - | - | - | - | - | - | - | - |
| Asset Growth % | 11.24% | 27.17% | -6.65% | 51.01% | 225.38% | -19.96% | -9.11% | 12.59% | 12.25% |
| Total Current Liabilities | 2.47M | 3.18M | 4.61M | 4.1M | 3.98M | 4.53M | 5.78M | 35.81M | 44.91M |
| Accounts Payable | 602.43K | 1.57M | 2.71M | 1.86M | 1.28M | 1.17M | 2.93M | 4.93M | 13.69M |
| Days Payables Outstanding | 83.54K | 327.61K | 1000K | 4.45K | 2.83K | 2.37K | 5.5K | 8.58K | 23.33K |
| Short-Term Debt | 172.97K | 172.97K | 172.97K | 172.97K | 177.24K | 196.99K | 218.38K | 241.55K | 1M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 320.52K | 1.65M | 1.73M | 1.57M | -218.38K | -241.55K | 30.13M |
| Current Ratio | 1.39x | 3.16x | 1.72x | 3.41x | 18.28x | 9.84x | 5.95x | 0.40x | 0.62x |
| Quick Ratio | 1.39x | 3.16x | 1.72x | 3.41x | 18.28x | 9.84x | 5.95x | 0.17x | 0.13x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 1.75M | 4.99M | 6.01M | 5.66M | 6.04M | 6.4M | 6.74M | 8.5M |
| Long-Term Debt | 0 | 0 | 0 | 164.58K | 0 | 0 | 0 | 0 | 724.92K |
| Capital Lease Obligations | 0 | 0 | 0 | 855.47K | 678.23K | 481.25K | 262.87K | 21.32K | 724.92K |
| Deferred Tax Liabilities | 0 | 0 | 4.99M | 4.99M | 4.99M | 5.56M | 6.14M | 6.71M | 7.77M |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -724.92K |
| Total Liabilities | 2.47M | 3.18M | 4.61M | 10.1M | 9.65M | 10.57M | 12.18M | 42.55M | 53.41M |
| Total Debt | 172.97K | 172.97K | 172.97K | 1.35M | 855.47K | 678.23K | 481.25K | 262.87K | 1.81M |
| Net Debt | -3.03M | -9.01M | -7.72M | -12.51M | -69.22M | -41.03M | -26M | -2.99M | -3.44M |
| Debt / Equity | 0.01x | 0.01x | 0.01x | 0.04x | 0.01x | 0.01x | 0.01x | 0.00x | 0.02x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -11.74x | -870.64x | -948.63x | -1130.01x | -2171.04x | -132.52x | - | - | -143.87x |
| Total Equity | 21.95M▲ 0% | 27.87M▲ 27.0% | 24.38M▼ 12.5% | 33.67M▲ 38.1% | 132.78M▲ 294.4% | 103.43M▼ 22.1% | 91.43M▼ 11.6% | 74.1M▼ 19.0% | 77.53M▲ 4.6% |
| Equity Growth % | 30.9% | 26.97% | -12.51% | 38.12% | 294.36% | -22.11% | -11.6% | -18.95% | 4.62% |
| Book Value per Share | 60.05 | 38.95 | 18.14 | 12.90 | 18.34 | 10.62 | 9.06 | 6.39 | 7.01 |
| Total Shareholders' Equity | 21.95M | 27.87M | 24.38M | 33.67M | 132.18M | 102.83M | 90.83M | 70.08M | 67.55M |
| Common Stock | 8.35K | 16.2K | 28.93K | 55.58K | 145.98K | 146.21K | 158.86K | 7.25K | 18.07K |
| Retained Earnings | -27.72M | -40.26M | -55.82M | -70.59M | -96.05M | -129.69M | -162.23M | -201.37M | -238.8M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 600.38K | 600.38K | 600.38K | 4.02M | 9.98M |
CTXR Cash Flow Statement
Citius Pharmaceuticals, Inc. (CTXR) cash flow — operating, investing & free cash flow history
| Line item | Sep'17 | Sep'18 | Sep'19 | Sep'20 | Sep'21 | Sep'22 | Sep'23 | Sep'24 | Sep'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -7.97M | -11.32M | -12.44M | -16.93M | -24.25M | -28.36M | -29.06M | -28.2M | -26.55M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | -35.1% | -41.99% | -9.89% | -36.12% | -43.23% | -16.95% | -2.46% | 2.96% | 5.85% |
| Net Income | -10.38M | -12.54M | -15.56M | -17.55M | -23.05M | -33.64M | -32.54M | -39.43M | -39.74M |
| Depreciation & Amortization | 2.63K | 1.75K | 893 | 152.36K | 164.87K | 179.68K | 194.32K | 209.61K | 214.25K |
| Stock-Based Compensation | 986.62K | 779.7K | 715.98K | 803.26K | 1.45M | 3.91M | 6.62M | 11.84M | 10.84M |
| Deferred Taxes | 0 | -450K | 0 | 0 | -166.56K | 576K | 576K | 576K | 1.06M |
| Other Non-Cash Items | 1.31M | 377.2K | 211.6K | 528.77K | 68K | 378.2K | 102K | 284.18K | 26.6K |
| Working Capital Changes | 115.52K | 509.85K | 2.2M | -866.97K | -2.72M | 239.56K | -4.01M | -1.69M | 1.05M |
| Change in Receivables | 0 | -818.34K | 818.34K | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | -818.34K | 0 | 0 | 0 | 0 | -2.13M | -12.65M |
| Change in Payables | -306.73K | 971.01K | 1.14M | -857.31K | -579.14K | -111.72K | 1.76M | 2M | 8.77M |
| Cash from Investing | -2.13K | 0 | 0 | -1.83K | -40.01M | 0 | 0 | -5M | -5.75M |
| Capital Expenditures | -2.13K | 0 | 0 | -1.83K | -40.01M | 0 | 0 | 0 | -5.75M |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -5M | 0 |
| Cash from Financing | 10.88M | 17.3M | 11.15M | 22.9M | 120.47M | 0 | 13.83M | 9.97M | 33.3M |
| Debt Issued (Net) | 4.21M | 0 | 0 | 164.58K | -172.97K | 0 | 0 | 0 | 1M |
| Equity Issued (Net) | 0 | 1000K | 1000K | 1000K | 1000K | 0 | 1000K | 1000K | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 6.67M | 1.13M | 23.22K | 7.16M | 31.21M | 0 | 31.27K | -3.83M | 0 |
| Net Change in Cash | 2.91M▲ 0% | 5.98M▲ 105.5% | -1.29M▼ 121.6% | 5.97M▲ 562.4% | 56.21M▲ 842.2% | -28.36M▼ 150.5% | -15.23M▲ 46.3% | -23.23M▼ 52.5% | 1M▲ 104.3% |
| Free Cash Flow | -7.97M▲ 0% | -11.32M▼ 41.9% | -12.44M▼ 9.9% | -16.93M▼ 36.1% | -64.26M▼ 279.5% | -28.36M▲ 55.9% | -29.06M▼ 2.5% | -28.2M▲ 3.0% | -26.55M▲ 5.8% |
| FCF Margin % | - | - | - | - | - | - | - | - | - |
| FCF Growth % | -35.13% | -41.95% | -9.89% | -36.14% | -279.49% | 55.86% | -2.46% | 2.96% | 5.85% |
| FCF per Share | -21.81 | -15.82 | -9.25 | -6.49 | -8.88 | -2.91 | -2.88 | -2.43 | -2.40 |
| FCF Conversion (FCF/Net Income) | 0.77x | 0.90x | 0.80x | 0.96x | 1.05x | 0.84x | 0.89x | 0.72x | 0.71x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CTXR Key Ratios
Citius Pharmaceuticals, Inc. (CTXR) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -102.85% | -53.65% | -50.33% | -59.64% | -60.46% | -27.79% | -28.48% | -33.4% | -47.29% | -49.38% |
| Return on Invested Capital (ROIC) | -70.57% | -41.54% | -54.76% | -65.89% | -70.24% | -41.66% | -39.68% | -43.1% | -46.13% | -39.53% |
| Debt / Equity | 0.04x | 0.01x | 0.01x | 0.01x | 0.04x | 0.01x | 0.01x | 0.01x | 0.00x | 0.02x |
| Interest Coverage | -828.25x | -11.74x | -870.64x | -948.63x | -1130.01x | -2171.04x | -132.52x | - | - | -143.87x |
| FCF Conversion | 0.71x | 0.77x | 0.90x | 0.80x | 0.96x | 1.05x | 0.84x | 0.89x | 0.72x | 0.71x |
CTXR Frequently Asked Questions
Citius Pharmaceuticals, Inc. (CTXR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Citius Pharmaceuticals, Inc. (CTXR) grew revenue by 0.0% over the past year. Growth has been modest.
Citius Pharmaceuticals, Inc. (CTXR) reported a net loss of $37.4M for fiscal year 2025.
Dividend & Returns
Citius Pharmaceuticals, Inc. (CTXR) has a return on equity (ROE) of -49.4%. Negative ROE indicates the company is unprofitable.
Citius Pharmaceuticals, Inc. (CTXR) had negative free cash flow of $26.6M in fiscal year 2025, likely due to heavy capital investments.
Explore More CTXR
Citius Pharmaceuticals, Inc. (CTXR) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates